"Pyrazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterocyclic aromatic organic compounds with the chemical formula C4H4N2.
| Descriptor ID |
D011719
|
| MeSH Number(s) |
D03.383.679
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrazines".
Below are MeSH descriptors whose meaning is more specific than "Pyrazines".
This graph shows the total number of publications written about "Pyrazines" by people in this website by year, and whether "Pyrazines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1995 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 2 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 5 | 9 |
| 2012 | 4 | 2 | 6 |
| 2013 | 2 | 1 | 3 |
| 2014 | 1 | 3 | 4 |
| 2015 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 4 | 1 | 5 |
| 2020 | 2 | 1 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrazines" by people in Profiles.
-
Cocrystallization improves the tabletability of ligustrazine despite a reduction in plasticity. Int J Pharm. 2024 Apr 10; 654:123939.
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
-
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 06 09; 139(23):3366-3375.
-
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
-
Simultaneous improvement of physical stability, dissolution, bioavailability, and antithrombus efficacy of Aspirin and Ligustrazine through cocrystallization. Int J Pharm. 2022 Mar 25; 616:121541.
-
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM). Br J Cancer. 2021 08; 125(4):582-592.
-
BRD4 modulates vulnerability of triple-negative breast cancer to targeting of integrin-dependent signaling pathways. Cell Oncol (Dordr). 2020 Dec; 43(6):1049-1066.
-
A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020 10 15; 126(20):4485-4497.
-
Simultaneous taste-masking and oral bioavailability enhancement of Ligustrazine by forming sweet salts. Int J Pharm. 2020 Mar 15; 577:119089.
-
Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy. J Diabetes Res. 2019; 2019:2756020.